Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients

• Published in: PloS one 2014-09, Vol.9 (9), p.e107470-e107470
• Main Authors: De Chiara, Loretta, Rodríguez-Piñeiro, Ana M, Cordero, Oscar J, Vázquez-Tuñas, Lidia, Ayude, Daniel, Rodríguez-Berrocal, Francisco J, de la Cadena, María Páez
• Format: Article
• Language: English
• Subjects: Aged; Antigens; Biomarkers, Tumor - blood; Cancer; Cancer patients; Carbohydrates; Carcinoembryonic antigen; Care and treatment; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - blood; Colorectal Neoplasms - pathology; Colorectal Neoplasms - surgery; Diagnosis; Dipeptidyl Peptidase 4 - blood; Dipeptidyl-peptidase IV; Epidemiology; Female; Humans; Liver Neoplasms - blood; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Lymphatic system; Male; Medical diagnosis; Medical screening; Medicine and Health Sciences; Metastases; Metastasis; Middle Aged; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - prevention & control; Patients; ROC Curve; Serum levels; Surveillance; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0107470

One of the main aims of the follow-up after curative resection of colorectal cancer is the early detection and treatment of tumor recurrence. We previously demonstrated decreased preoperative soluble CD26 (sCD26) levels in serum from colorectal cancer patients. We extended now the study to investigate if sCD26 levels in postoperative serum serve as marker of recurrence of the disease during surveillance. Soluble sCD26 was measured in pre- and postoperative serum samples of 43 patients with primary colorectal cancer. Carcinoembryonic antigen, carbohydrate antigen 19.9 and 72.4 levels were also measured during surveillance. The average follow-up period was 41.8 ± 20.8 months. sCD26 levels during follow-up showed well-defined patterns in patients without disease (n = 28), and in patients with tumor persistence (n = 2), local recurrence (n = 3) or distant metastasis (n = 10). Disease-free patients showed stable levels between 460-850 ng/mL during follow-up, while high (over 850 ng/mL) and unstable sCD26 levels were found before recurrence was diagnosed. The mean maximum/minimum sCD26 ratios during surveillance were 1.52, 2.12 and 2.63 for patients with no recurrence, local recurrence and metastasis, respectively (p = 0.005). From the cut-off obtained from a receiver operator characteristics (ROC) curve built with the maximum/minimum sCD26 ratios and the upper and lower cut-offs of sCD26, we were able to discriminate patients with and without recurrent disease. We propose that the measurement of serum sCD26 during the follow-up of patients diagnosed of colorectal cancer could be valuable for the early detection of local and distant recurrence. A large, randomized, prospective trial should be performed to confirm our findings.